Eris Lifesciences Limited
ERIS.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$162.56B
Close$
$686.98
41.3% downside
Current Fair Value
41.3% downsideOvervalued by 41.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $162.56 Billion |
|---|---|
| Enterprise Value | $185.56 Billion |
| Dividend Yield | $7.21 (0.62%) |
| Earnings per Share | $45.33 |
| Beta | -0.04 |
| Outstanding Shares | 136,704,000 |
Return
| Return on Equity | 16.50% |
|---|---|
| Return on Assets | 8.74% |
| Return on Invested Capital | 16.03% |
Valuation & Multiples
| P/E Ratio | 24.9 |
|---|---|
| PEG | 120.4 |
| Price to Sales | 4.96 |
| Price to Book Ratio | 4.12 |
| Enterprise Value to Revenue | 5.75 |
| Enterprise Value to EBIT | 21.89 |
| Enterprise Value to Net Income | 28 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.61 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$10.77
Average shareholder expectationRevenue Estimate
$8.63 B
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$10.78
Average shareholder expectationRevenue Estimate
$8.93 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Eris Lifesciences Limited
2,758 employees
CEO: Amit Indubhushan Bakshi Eris Lifesciences Ltd., along with its affiliated companies, operates in India, specializing in the production, promotion, and supply of proprietary pharmaceutical drugs aimed at treating chronic and semi-chronic health conditions. The c...